<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03436992</url>
  </required_header>
  <id_info>
    <org_study_id>E2 and D</org_study_id>
    <secondary_id>1R01HL137087-01A1</secondary_id>
    <nct_id>NCT03436992</nct_id>
  </id_info>
  <brief_title>Estrogen and Diabetes</brief_title>
  <official_title>Estrogen-Mediated Impairments of Vascular Health in Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes has recently been referred to as &quot;the epidemic of the 21st century&quot;. The reason why
      women with type 1 diabetes have a 2-3 fold greater risk of cardiovascular disease (CVD)
      compared to men with type 1 diabetes is unknown.The purpose of this study is to investigate
      whether or not estrogen contributes to vascular dysfunction in premenopausal women with
      diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Flow-Mediated Dilation (FMD)</measure>
    <time_frame>change in FMD at 2hrs</time_frame>
    <description>The change in FMD at ~2hrs from baseline values</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Women with type 1 diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with type 1 diabetes will be randomly assigned to 1 of the 3 interventions (Antioxidant cocktail, Resveratrol, or placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control women</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy women who participate will receive no intervention and serve as controls.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Men with type 1 diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Men with type 1 diabetes will be randomly assigned to 1 of the 3 interventions (AOX cocktail, Resveratrol, or placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Antioxidant Cocktail</intervention_name>
    <description>Vitamin C, Vitamin E, alpha lipoic acid</description>
    <arm_group_label>Women with type 1 diabetes</arm_group_label>
    <arm_group_label>Men with type 1 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>270mg trans-resveratrol</description>
    <arm_group_label>Women with type 1 diabetes</arm_group_label>
    <arm_group_label>Men with type 1 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Women with type 1 diabetes</arm_group_label>
    <arm_group_label>Men with type 1 diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both men and premenopausal

          -  Normal menstrual cycle interval of 25-35 days for at least 3 previous cycles

          -  All races

          -  Clinical diagnosis of insulin-dependent type 1 diabetes (patients only)

        Exclusion Criteria:

          -  Clinical diagnosis of hepatic, cardiovascular, or renal disease

          -  Uncontrolled Diabetes (HbA1c&gt;9%)

          -  Diabetic complications (i.e. macrovascular, microvascular, or autonomic)

          -  Proteinuria

          -  Uncontrolled Hypertension (&gt;140/90 mmHg on therapy)

          -  Hormonal use of birth control (past 3 months)

          -  Pregnancy

          -  Oligomenorrhea

          -  Direct vasoactive medications (i.e. nitrates)

          -  Anti-estrogens (i.e. SERMs)

          -  Plycystic ovarian syndrome (defined by NIH guidelines-hyperandrogenic anovulation)

          -  Undetectable Anti-Mullerian Hormone (AMH) following screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Harris, PhD, CES</last_name>
    <role>Principal Investigator</role>
    <affiliation>Augusta University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacob Looney, BS</last_name>
    <phone>706-721-5483</phone>
    <email>jlooney@augusta.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ryan Harris, PhD, CES</last_name>
    <phone>706-721-5998</phone>
    <email>ryharris@augusta.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan A Harris, PhD</last_name>
      <phone>706-721-5998</phone>
      <email>ryharris@augusta.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgia Prevention Institute</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Harris, Ph.D.</last_name>
      <phone>706-721-5998</phone>
      <email>ryharris@gru.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nichole Seigler, BA</last_name>
      <phone>706-721-5998</phone>
      <email>maseigler@gru.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Augusta University</investigator_affiliation>
    <investigator_full_name>Ryan Harris</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Estrogen, Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

